...
首页> 外文期刊>Pharmacognosy magazine >Antibacterial Synergy of Silver Nanoparticles with Gentamicin and Chloramphenicol against Enterococcus faecalis
【24h】

Antibacterial Synergy of Silver Nanoparticles with Gentamicin and Chloramphenicol against Enterococcus faecalis

机译:银纳米颗粒与庆大霉素和氯霉素对粪肠球菌的抗菌协同作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Enterococcus faecalis (Ef) is a multidrug-resistant pathogenic bacteria associated with hospital-acquired infections. Ef is involved in a number of infectious diseases. It generally infects patients with the weekend immune system, i.e. a person mostly acquires Ef infections in the hospital, especially in intensive care units and thus, is more likely to be resistant to many antibiotics. Development of resistance against various antibiotics and emergence of drug-resistant strains is a growing global concern. Objective: Due to the unselective use of antibiotics for a long time multidrug resistant bacteria and extensively drug-resistant, which is now posing a new challenge to the medical community. To treat infections caused by Ef, the synergistic effect of different antibiotics with silver nanoparticles (AgNPs) was tested against Ef. Materials and Methods: In the present study, synthesis of AgNPs was carried out from the cell-free supernatant of Klebsiella pneumoniae . AgNPs were characterized using various techniques, namely, ultraviolet-visible spectrophotometry, transmission electron microscopy, and Fourier transform infrared spectroscopy. Moreover, process optimization was done for enhanced production of AgNPs. In addition, antimicrobial activity of the nanoparticles was also tested. Furthermore, the nanoparticles were evaluated for their antimicrobial activities in combination with gentamicin and chloramphenicol, against Ef. Results: The results showed that the combination of gentamicin and chloramphenicol with AgNPs has a better antibacterial effect. To add to this, hemolytic activity of AgNPs was evaluated against human red blood corpuscles (RBCs). AgNPs were found to be nontoxic to RBCs. Conclusion: The collective effect of AgNps with Gentamicin and Chloramphenicol was more as compared to AgNps alone which indicate the synergistic effect of these components. These observations show the potential of AgNPs in combination with above-stated antibiotics against Ef infections. SUMMARY Enterococcus faecalis (Ef) is a multidrug-resistant bacteria with is resistant to wide range of antibiotics Due to this increasing resistance, there is a need to find a new approach to overcome the infections caused by Ef The combined effect of silver nanoparticles (AgNPs) with gentamicin and chloramphenicol was notably seen against Ef Furthermore, the AgNPs were nontoxic to the human red blood corpuscles which confirm its nontoxic nature. Abbreviations used: Ef: Enterococcus faecalis , MDR: Multidrug resistance, AgNPs: Silver nanoparticles, Kp: Klebsiella pneumoniae , RBCs: Red blood corpuscles, ENPs: Engineered nanoparticles, FTIR: Fourier transform infrared spectroscopy, TEM: Transmission electron microscopy, AgNO3: Silver nitrate, EDTA: Ethylenediaminetetraacetic acid, PBS: Phosphate-buffered saline.
机译:背景:粪肠球菌(Ef)是一种与医院获得性感染有关的多药耐药性致病菌。 Ef涉及多种传染病。它通常感染周末免疫系统的患者,即一个人通常在医院,特别是在重症监护病房中感染Ef感染,因此更可能对多种抗生素具有抗药性。对各种抗生素的耐药性的发展和耐药菌株的出现是全球日益关注的问题。目的:由于长期以来一直非选择性使用抗生素,对多种药物具有耐药性,并且对多种药物具有广泛的耐药性,这对医学界构成了新的挑战。为了治疗由Ef引起的感染,测试了不同抗生素与银纳米颗粒(AgNPs)对Ef的协同作用。材料和方法:在本研究中,从肺炎克雷伯菌的无细胞上清液中合成AgNPs。使用各种技术对AgNPs进行表征,即紫外可见分光光度法,透射电子显微镜和傅里叶变换红外光谱。此外,进行了工艺优化以提高AgNP的产量。另外,还测试了纳米颗粒的抗微生物活性。此外,评估了纳米颗粒与庆大霉素和氯霉素联用对Ef的抗菌活性。结果:结果表明,庆大霉素和氯霉素与AgNPs的结合具有更好的抗菌效果。除此之外,还评估了AgNPs对人类红血球(RBC)的溶血活性。发现AgNP对RBC无毒。结论:与单独的AgNps相比,AgNps与庆大霉素和氯霉素的集体效应更大,这表明这些成分具有协同作用。这些观察结果表明,AgNP与上述针对Ef感染的抗生素联合使用的潜力。总结粪肠球菌(Ef)是一种对多种抗生素具有耐药性的多药耐药细菌由于这种耐药性的不断提高,需要找到一种新的方法来克服由Ef引起的感染。银纳米颗粒(AgNPs)的综合作用)含有庆大霉素和氯霉素的抗Ef效果尤为明显。此外,AgNPs对人的红血球无毒,证实了其无毒性质。使用的缩写:Ef:粪肠球菌,MDR:耐多药,AgNPs:纳米银颗粒,Kp:肺炎克雷伯菌,RBC:红血球,ENPs:工程纳米颗粒,FTIR:傅里叶变换红外光谱,TEM:透射电子显微镜,AgNO 3 :硝酸银,EDTA:乙二胺四乙酸,PBS:磷酸盐缓冲液。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号